NMDA Receptor Antibody Detection for Autoimmune Encephalitis Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing autoimmune encephalitis and identifying tumor-related epileptic seizures are inadequate, as they are poorly responsive to treatments and lack reliable diagnostic tools for detecting antibodies associated with these conditions.
Innovation Solution
Testing a subject's body fluid for antibodies to the NR subunit of the NMDA receptor to determine the cause of encephalitis or epilepsy and diagnose the presence of a tumor, as the presence of these antibodies indicates an autoimmune etiology or tumor involvement.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current diagnostic methods are used for autoimmune encephalitis, then diagnosis can be made, but the diagnostic reliability and treatment responsiveness are poor
Solution Approach 1:
The patent segments the diagnostic approach by specifically targeting the detection of antibodies against NR1 and NR2 subunits of the NMDA receptor, rather than using general encephalitis diagnostic methods. This segmentation allows for more reliable and specific diagnosis of autoimmune encephalitis by focusing on the particular autoimmune mechanism involved.
Solution Approach 2:
The patent introduces antibody detection as an intermediary diagnostic tool that mediates between clinical symptoms and underlying autoimmune pathology. By detecting antibodies against NMDA receptor subunits, the method provides a reliable bridge to confirm autoimmune etiology and guide appropriate immunotherapy.
2Productivity
If general diagnostic approaches are used, then treatment can be initiated, but neurologic outcomes are poor due to delayed or inaccurate diagnosis
Solution Approach 1:
The patent enables preliminary identification of autoimmune etiology through specific antibody detection before initiating treatment. By testing for antibodies against NR1 and NR2 subunits early in the diagnostic process, clinicians can promptly identify autoimmune encephalitis and start appropriate immunotherapy, avoiding delays associated with general diagnostic approaches.
Solution Approach 2:
The patent changes the diagnostic parameter from general encephalitis markers to specific antibody presence against NMDA receptor subunits. This parameter change enables more accurate and faster identification of autoimmune cases, improving treatment efficiency and reducing time to appropriate intervention.
3Measurement precision
If tumor screening is performed, then tumor detection is possible, but the ability to identify tumor-related epilepsy is insufficient
Solution Approach 1:
The patent creates a universal diagnostic approach that serves multiple functions: detecting autoimmune encephalitis, identifying tumor-related epilepsy, and determining etiology. By testing for antibodies against NMDA receptor subunits, the same diagnostic method adapts to identify different underlying causes including tumors, providing both precision and versatility.
Solution Approach 2:
The patent introduces antibody detection as a feedback mechanism that provides information about both autoimmune status and potential tumor involvement. The presence and titer of antibodies against NR1 and NR2 subunits give feedback that helps distinguish tumor-related cases from other autoimmune encephalitis, enhancing both detection accuracy and diagnostic versatility.
Data Source
Figure 1
Figure 2A~2C
Figure 3A~3E
AI summary
This invention provides methods of diagnosing or determining a cause of an autoimmune encephalitis or an epilepsy in a subject and of diagnosing a tumor in a subject, comprising the step of testing a body fluid of the subject for an antibody to an NR subunit of the NMDA receptor.